Bronchobos capsules, 375mg, # 30

Release form, composition and packaging

Hard gelatin capsules, size No. 0, opaque, yellow

the contents of the capsules are white powder.

1 caps.

carbocisteine ​​375 mg

corn starch - 23 mg, magnesium stearate - 2 mg, gelatin - 8 mg, colloidal silicon dioxide - 2 mg.

10 pieces.

- blisters (3) - cardboard packs.

pharmachologic effect

Mucolytic and expectorant drug.

Mucolytic and expectorant action is due to the activation of sialic transferase - an enzyme of the goblet cells of the bronchial mucosa.

Normalizes the quantitative ratio of acidic and neutral sialomucins of bronchial secretions.

Reduces the viscosity of bronchial secretions and discharge from the paranasal sinuses, facilitates the discharge of sputum and mucus, and reduces coughing.

Promotes regeneration of the mucous membrane, normalizes its structure, activates the activity of the ciliated epithelium.

Restores the secretion of IgA immunoglobulin (specific protection) and the number of sulfhydryl groups of mucus components (non-specific protection), improves mucociliary clearance.

Pharmacokinetics

Absorption and distribution

Carbocisteine ​​is rapidly absorbed after oral administration.

Bioavailability is low (less than 10% of the dose taken).

Cmax in blood serum and in the mucous membrane of the respiratory tract is achieved 2-3 hours after taking the drug inside and remains in the mucous membrane for 8 hours.

Metabolism and excretion

It is metabolized in the liver (has a first pass" effect through the liver).

It is excreted mainly by the kidneys, partly unchanged, partly in the form of metabolites.

T1 / 2 - about 2 hours

Indications for use

- acute and chronic bronchopulmonary diseases, accompanied by the formation of viscous, difficult to separate sputum (tracheitis, bronchitis, tracheobronchitis, bronchial asthma, bronchiectasis)

- inflammatory diseases of the middle ear (otitis media)

- inflammatory diseases of the nose and its paranasal sinuses (rhinitis, sinusitis)

- preparation for bronchoscopy and / or bronchography.

Contraindications for use

- hypersensitivity to carbocisteine ​​and other components of the drug

- peptic ulcer of the stomach and duodenum in the acute phase

- chronic glomerulonephritis in the acute phase

- cystitis

- liver disease (for taking syrup)

- alcoholism (for taking syrup)

- epilepsy (for taking syrup)

- trauma or diseases of the brain (for taking syrup)

- pregnancy

- lactation (breastfeeding)

- children's age up to 3 years (for taking syrup 2.5%)

- children under 15 years of age (for taking capsules and syrup 5%).

With caution: with chronic glomerulonephritis (in history), gastric ulcer and duodenal ulcer (in history), in II-III trimesters of pregnancy and during breastfeeding.

Dosage regimen

The drug is administered orally.

Capsules

Adults and adolescents over 15 years old: 750 mg (2 capsules) 3 times / day.

After reaching the therapeutic effect, the daily dose is reduced to 1.5 g: 750 mg (2 capsules) 2 times / day.

Treatment should not be continued for more than 8-10 days without consulting a doctor.

Syrup

To dose the syrup, a 5 ml measuring spoon, graduated to 2.5 ml, should be used.

1 scoop of 5% syrup (5 ml) = 250 mg carbocysteine

1 scoop 2.5% syrup (5 ml) = 125 mg carbocysteine

Adults: 15 ml (3 measuring spoons) 5% syrup 3 times / day.

Children aged 3-6 years: 5 ml (1 scoop) 2.5% syrup 2-4 times / day.

Children over the age of 6 years: 5-10 ml (1-2 scoops) 2.5% syrup 3 times / day.

Overdose

Symptoms: stomach pain, nausea, diarrhea.

Treatment: symptomatic.

Side effect

From the digestive system: sometimes - nausea, vomiting, diarrhea, epigastric pain, gastrointestinal bleeding.

Allergic reactions: in isolated

Name ENG

BRONCHOBOS

Clinical and pharmacological group

Mucolytic drug

ATX code

Carbocisteine

Dosage

375mg

Structure

1 capsule contains: active substance: carbocisteine ​​375.0 mg

excipients: corn starch - 23 mg

magnesium stearate - 2 mg

gelatin - 8 mg

colloidal silicon dioxide - 2 mg.

Indications

acute and chronic bronchopulmonary diseases, accompanied by a violation of the formation and excretion of mucus (tracheitis, bronchitis, tracheobronchitis, bronchial asthma, bronchiectasis)

inflammatory diseases of the middle ear and paranasal sinuses (rhinitis, otitis media, sinusitis)

preparation of the patient for bronchoscopy or bronchography.

INN / Active ingredient

carbocisteine

Contraindications

hypersensitivity to the drug or its auxiliary components

peptic ulcer of the stomach and duodenum in the acute stage

chronic glomerulonephritis (in the acute phase)

cystitis

children under 15 years old

pregnancy (I trimester).

With care: gastric ulcer and duodenal ulcer (in history), chronic glomerulonephritis (in history), pregnancy (II – III trimesters), breastfeeding.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Specifications

Category

Cough

,

Thinning phlegm

,

Expectorants

Scope of the drug

Respiratory system

Release form

Capsules

Manufacturer country

Bosnia and Herzegovina

Package quantity, pcs

thirty

Scope of application

Gastroenterology

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Bosnalek +

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Expectorant mucolytic agent

Anatomical and therapeutic characteristics

R05CB03 Carbocisteine

Dosage form

Capsules

Dosage (volume) of the substance in the preparation

375 mg

Expiration date in days

1095

Package weight, g

45

Mode of application

:

Adults and adolescents over 15 years old - 750 mg (2 capsules) 3 times a day.

After reaching the therapeutic effect, the daily dose is reduced to 1.5 g - 750 mg (2 capsules) 2 times a day.

Treatment should not be continued for more than 8-10 days without consulting a doctor.

Information on technical characteristics, delivery set, country of manufacture "